Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,396JPY
22 Jan 2018
Change (% chg)

¥13 (+0.94%)
Prev Close
¥1,384
Open
¥1,384
Day's High
¥1,397
Day's Low
¥1,384
Volume
5,383,000
Avg. Vol
7,200,821
52-wk High
¥1,570
52-wk Low
¥1,332

Latest Key Developments (Source: Significant Developments)

Astellas Pharma says application of marketing approval for blinatumomab in Japan
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co.  Full Article

Astellas acquires Mitobridge under existing collaboration
Friday, 1 Dec 2017 

Nov 30 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ACQUIRES MITOBRIDGE UNDER EXISTING COLLABORATION.SAYS ‍MITOBRIDGE WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF ASTELLAS FOLLOWING CLOSE OF ACQUISITION​.  Full Article

Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seattle Genetics Inc :Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer.Primary objective of trial is to assess safety and tolerability of Enfortumab Vedotin in combination with CPI therapy​.  Full Article

Astellas Pharma completes share repurchase
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Astellas Pharma Inc <4503.T>:Says it completed repurchase of 49.3 million shares of its common stock, for 70 billion yen in total, as of Oct. 31 .  Full Article

FDA grants fast track status to Astellas for acute myeloid leukemia drug
Wednesday, 11 Oct 2017 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>-:U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia.  Full Article

Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>::Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.Seattle Genetics Inc - ‍companies also plan to initiate a combination trial of enfortumab vedotin with CPI therapy in late 2017​.  Full Article

Astellas Pharma to repurchase shares
Friday, 28 Jul 2017 

July 28(Reuters) - Astellas Pharma Inc <4503.T>:Says it will repurchase up to 50 million shares, representing 2.4 percent of outstanding.Says share repurchase price up to 70 billion yen in total.Says repurchase period from July 31 to Oct. 31.  Full Article

Astellas Pharma files lawsuit against patent infringement of Myrbetriq® in U.S.
Friday, 7 Oct 2016 

Astellas Pharma Inc <4503.T>:Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas’ mirabegron (generic name) product sold under the trademark Myrbetriq® in the U.S..  Full Article

Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan
Wednesday, 28 Sep 2016 

Astellas Pharma Inc <4503.T>:Says the co received a marketing approval of Kiklin® Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan.  Full Article

Astellas Pharma to create companion diagnostic for acute Myeloid Leukemia treatment-Nikkei<4503.T>
Monday, 15 Aug 2016 

Nikkei: Astellas Pharma to create with U.S. co so-called companion diagnostic for acute myeloid leukemia treatment the co has been working on-Nikkei . Astellas Pharma seeks to obtain approval in Japan, U.S. and elsewhere within three years-Nikkei .  Full Article

BUZZ-Vical: Falls as herpes vaccine fails late-stage trial

** Drugmaker's shares fall 27.81 pct to $1.35 - top pct loser among Nasdaq-listed stocks premarket